- Wall Street Analyst Who Sounded Alarm Over Prostate Cancer Drug Provenge In JNCI Settles with SEC Over Shorting Dendreon Stock
- An Earmark in the Making: NCI Urged to Boost Gastric Cancer Funding
- Johnson to Leave NCI Office of Communications
- FDA Expands Nexavar Indication to Include Thyroid Cancer

